(Sharecast News) - Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.
AstraZeneca said Enhertu, developed in conjunction with Daiichi Sankyo, had received US Food and Drug Administration approval in combination with pertuzumab for the first‑line...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE